+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07224425

Dose Finding and Expansion Trial of BI 3810944 in Adults With Advanced Solid Tumours and Melanoma

Led by Boehringer Ingelheim · Updated on 2026-10-30

69

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying BI 3810944 in adults with advanced solid tumours or melanoma who have not had success with previous treatments or have no treatment options. The study aims to find tolerable doses of BI 3810944, identify the most suitable dose, and assess whether it helps people with advanced cancer. This is a phase I trial sponsored by Boehringer Ingelheim. Participants receive BI 3810944 usually once every three weeks, with an initial period of once-weekly dosing. They may continue treatment for up to two years as long as they benefit. Early visits include hospital overnight stays. During treatment, participants have regular visits where doctors monitor health, perform lab tests, and record any side effects. Tumour size is regularly checked using imaging. Researchers measure outcomes such as occurrence of cytokine release syndrome, dose limiting toxicities, objective response, adverse events, duration of response, disease control, and progression-free survival. The total participation time can be up to 24 months with ongoing safety and response monitoring.

CONDITIONS

Brief Title

A Study of BI 3810944 in Patients With Advanced Cancer

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here